针对帕金森病的疾病修饰疗法的平台试验的优点和挑战
Margherita Fabbri1, Olivier Rascol1, Tom Foltynie2
1Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Center, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), French NS-Park/F-CRIN Network, University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France.
概括
主协议,就像平台试验一样,提供了有效的方法来测试帕金森病 (PD) 疗法. 虽然有望加速药物开发,但在PD患者异质性和结果措施方面的挑战需要解决才能取得成功.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 药物开发 药物开发
背景情况:
- 传统的帕金森病 (PD) 药物开发是缓慢而昂贵的.
- 包括平台试验在内的创新性主协议正在出现,以提高效率.
- 这些试验在一个总体协议下解决了多个研究问题.
研究的目的:
- 审查总体协议的潜力,特别是平台试验,用于开发PD的疾病修饰疗法.
- 讨论在PD研究中实施平台试验的优势和挑战.
- 检查当前的PD平台试验及其独特的目标,种群和结果.
主要方法:
- 审查主协议,专注于平台试验设计.
- 对将平台试验应用于帕金森病的具体挑战进行分析.
- 使用正在进行的PD平台试验示例的插图.
主要成果:
- 平台试验有可能提高PD治疗评估的效率和节省成本.
- 存在重大挑战,包括患者异质性,混治疗方法,以及对结果措施缺乏共识.
- 目前的PD平台试验针对不同的目标,患者群体和结果.
结论:
- 平台试验显示了加速新型PD疗法的评估的前景.
- 将理论上的好处转化为高质量的数据和成功的药物许可需要进一步的验证.
- 产业的参与和克服PD特定障碍对于这种方法的成功至关重要.
相关概念视频
01:24Parkinson's Disease: Treatment
254
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
254
01:15Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:28Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
01:16Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K